Press Releases

February 22, 2024
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
February 22, 2024
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
February 22, 2024
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
February 15, 2024
Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
February 13, 2024
Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
January 25, 2024
Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Additional Resources